Multiple Myeloma | Specialty

Benefits of Elotuzumab Sustained in 3-Year Myeloma Data

December 5th 2015

The combination of elotuzumab, lenalidomide, and dexamethasone showed sustained improvements in progression-free survival and overall survival for patients with relapsed/refractory multiple myeloma.

Bortezomib Triplet Therapy New Standard of Care for Untreated Multiple Myeloma

December 5th 2015

Induction therapy with a triplet of bortezomib, lenalidomide, and dexamethasone significantly improved progression-free survival and overall survival compared with lenalidomide and dexamethasone alone for patients with untreated multiple myeloma.

Carfilzomib Bests Bortezomib Across Multiple Myeloma Subgroups

December 5th 2015

Treatment with carfilzomib reduced the risk of progression or death by 47% compared with bortezomib for patients with relapsed multiple myeloma.

Dr. Usmani on Ibrutinib/Carfilzomib in Patients With Multiple Myeloma

December 4th 2015

Saad Z. Usmani, MD, hematology and medical oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses results of a phase Ib/II study examining the combination of ibrutinib plus carfilzomib in patients with relapsed/refractory multiple myeloma.

Three New Drug Approvals in 14 Days: An Amazing Fortnight for Multiple Myeloma Treatment

December 1st 2015

In a matter of 15 days, 3 new drugs have been approved for myeloma, namely daratumumab, ixazomib and elotuzumab.

UC Davis Meets NCI-Designation With Great Responsibility

November 30th 2015

Conference Highlights, Three FDA Approvals, and More

November 30th 2015

FDA Approves Elotuzumab for Multiple Myeloma

November 30th 2015

The FDA approved elotuzumab (Empliciti) for use in combination therapy in patients with multiple myeloma following the failure of 1 to 3 prior therapies.

FDA Approvals for Daratumumab and Osimertinib, Regulatory Advances in RCC and CLL, and More

November 21st 2015

FDA Approves Ixazomib for Relapsed Multiple Myeloma

November 20th 2015

The FDA has approved the oral proteasome inhibitor ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with multiple myeloma following progression on at least one prior therapy.

Dr. Sundar Jagannath on Significant Studies in Multiple Myeloma

November 18th 2015

Sundar Jagannath, MD, Professor Medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the significance of several recent studies in multiple myeloma.

FDA Approves Daratumumab for Pretreated Multiple Myeloma

November 16th 2015

The FDA has granted an accelerated approval to the CD38-targeted monoclonal antibody daratumumab as a monotherapy for patients with multiple myeloma following at least 3 prior therapies.

How Anderson Transformed Multiple Myeloma Care

November 12th 2015

Kenneth C. Anderson, MD, has helped transform multiple myeloma from an essentially untreatable disease to a chronic condition. He was honored in the Myeloma category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group has launched to honor leaders in the field.

New Blood Cancer Landscape Taking Shape

November 12th 2015

Experts discuss developments in CLL, myeloma, and Hodgkin lymphoma.

Biomarkers, Novel Agents Continue to Advance Multiple Myeloma Treatment

November 11th 2015

Shaji Kumar, MD, discusses how newly approved agents and other changes have affected the treatment of multiple myeloma and what is on the horizon for the disease.

Willem Overwijk Explains the Role of the Innate Immune System in Cancer Treatment

November 6th 2015

Willem Overwijk, PhD, Associate Professor, Department of Melanoma Medical Oncology, Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the role of innate immunity in the treatment of cancer.

Combinations Key to Optimizing Novel Antibodies in Myeloma

November 4th 2015

Optimizing outcomes with novel antibodies in multiple myeloma will involve combination regimens with established agents.

Dr. Landgren Discusses MRD Detection for Multiple Myeloma

November 4th 2015

C. Ola Landgren, MD, PhD, hematologic oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses minimal residual disease detection for progression-free survival and overall survival for patients with multiple myeloma.

FDA Issues Complete Response Letter for CE-Melphalan in Myeloma

October 23rd 2015

The FDA issued a complete response letter to Spectrum Pharmaceuticals, informing the company that its new drug application (NDA) for the use of Captisol-enabled melphalan in multiple myeloma will not be approved in its current form.

Future Role for HDAC Inhibition in Multiple Myeloma

October 15th 2015